EP Patent

EP3468562A1 — Combinations of linagliptin and metformin

Assigned to Boehringer Ingelheim International GmbH · Expires 2019-04-17 · 7y expired

What this patent protects

The present invention relates to combinations of Linagliptin with metformin for use int he treatment of metabolic diseases in patients having chronic kidney disease (CKD).

USPTO Abstract

The present invention relates to combinations of Linagliptin with metformin for use int he treatment of metabolic diseases in patients having chronic kidney disease (CKD).

Drugs covered by this patent

Patent Metadata

Patent number
EP3468562A1
Jurisdiction
EP
Classification
—
Expires
2019-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.